Internal Medicine
Clinical review: Treatment of opioid use disorder in primary care.
21 May, 2021 | 08:31h | UTCTreatment of opioid use disorder in primary care – The BMJ (free for a limited period)
M-A: In patients with anaphylaxis, the use of multiple epinephrine doses is necessary in 7.7% of cases.
21 May, 2021 | 08:19h | UTCCommentary: How Often Does Anaphylaxis Require Redosing of Epinephrine? – Journal Feed
Cohort study: 14% of adults aged 65 years or less who were infected with SARS-CoV-2 had at least one new type of clinical sequelae that required medical care after the acute phase of the illness.
20 May, 2021 | 08:59h | UTCEditorial: Unpacking post-covid symptoms – The BMJ
Commentary on Twitter (thread – click for more)
After covid infections, 14% of >266,000 people, age ≤ 65, developed at least 1 sequelae that required medical care #LongCovid Just out @bmj_latest @OptumLabs @mlipsitch Risk increased w/ pre-existing conditions but also found in healthy, age < 50 https://t.co/h8IlnRNp2v pic.twitter.com/e15uSj9BXN
— Eric Topol (@EricTopol) May 19, 2021
FDA In Brief: FDA advises against use of SARS-CoV-2 antibody test results to evaluate immunity or protection from COVID-19, including after vaccination.
20 May, 2021 | 08:55h | UTC
Commentary on Twitter (thread – click for more)
Today, we issued a safety communication notifying the public and providers that results from SARS-CoV-2 antibody tests should not be used to evaluate immunity or protection from #COVID19 at any time – especially after receiving a #COVID19 vaccination. https://t.co/KlywV04WYO pic.twitter.com/TPdIVxWzSh
— U.S. FDA (@US_FDA) May 19, 2021
Systematic review and meta-analysis of observational studies suggest low-dose aspirin may be of benefit for patients with Covid-19 – the finds require further investigation in randomized studies.
20 May, 2021 | 08:54h | UTC
One year after hospital discharge due to SARS-CoV-2 Infection, the prevalence of long-term cough, chest pain, dyspnea, and fatigue was 2.5%, 6.5%, 23.3%, and 61.2%, respectively
20 May, 2021 | 08:57h | UTCPrevalence of Post-COVID-19 Cough One Year After SARS-CoV-2 Infection: A Multicenter Study – Lung
SPRINT Trial final report: targeting a systolic BP of less than 120 mm Hg in patients at increased CV risk is associated with improved CV and mortality outcomes but increases the risk of serious adverse events.
20 May, 2021 | 08:36h | UTC
Characteristics associated with Multisystem Inflammatory Syndrome among adults with SARS-CoV-2 infection
20 May, 2021 | 08:52h | UTCCommentary: COVID-related inflammatory syndrome looks different in adults – CIDRAP
M-A: Psychologic treatment of depression compared with pharmacotherapy and combined treatment in primary care – Psychotherapy has comparable effects to those of pharmacotherapy, and combined treatment might be better than either psychotherapy or pharmacotherapy alone.
20 May, 2021 | 08:34h | UTC
Commentary on Twitter
https://twitter.com/pimcuijpers/status/1391999860505825286
Systematic review: Prognostic factors for pain chronicity in low back pain – “Higher pain intensity, higher body weight, carrying heavy loads at work, difficult working positions, and depression were the most frequently observed risk factors for chronic low back pain”
20 May, 2021 | 08:32h | UTCPrognostic factors for pain chronicity in low back pain: a systematic review – Pain Reports
A pharmacist-led penicillin allergy assessment program can delabel many “penicillin allergic” patients through allergy histories and penicillin skin testing. The program was associated with reduced use of high Clostridioides difficile infection–risk antibiotics.
20 May, 2021 | 08:30h | UTC
Commentaries on Twitter
🆕💥💥 @jamanetworkopen
Evaluation of a Pharmacist-Led Penicillin Allergy Assessment Program and Allergy Delabeling in a 3ry Care Hospital
Phase 1 : Allergy histories
Phase 2 :Allergy histories +Penicillin Skin Testing #IDTwitter https://t.co/pZfVf8TJIn pic.twitter.com/2VvnaCayqj— Antibiotic Steward Bassam Ghanem 🅱️C🆔🅿️🌟 (@ABsteward) May 13, 2021
This cross-sectional study found pharmacist-driven allergy assessments may help improve antibiotic selection and clinical outcomes for patients and hospitals https://t.co/io5LcU9U9U
— JAMA Network Open (@JAMANetworkOpen) May 13, 2021
ESC Comprehensive review: Update on management of hypokalemia and goals for the lower potassium level in patients with cardiovascular disease.
20 May, 2021 | 08:26h | UTC
Commentary on Twitter
Learn about the management of hypokalemia: a comprehensive review from the ESC WG on cardiovascular pharmacotherapy https://t.co/MkwOZyvUJA@AgewallStefan @GianluSava #EHJPharmacotherapy #cardiotwitter pic.twitter.com/tUFVmycwHa
— European Society of Cardiology Journals (@ESC_Journals) May 15, 2021
24-week randomized controlled trial: Mixed tree nut snacks resulted in similar weight loss and increased satiety compared to refined carbohydrate snacks in a weight loss and maintenance program.
20 May, 2021 | 08:28h | UTCCommentary: Mixed tree nut snacks result in significant weight loss and improved satiety – News Medical
[Preprint] RECOVERY Trial: Colchicine does not improve outcomes in patients admitted to hospital with COVID-19.
19 May, 2021 | 08:51h | UTC
Commentary on Twitter (thread – click for more)
RECOVERY pre-print: Colchicine
11340 patients hospitalised with COVID-19
Randomised to colchicine vs usual care
No significant improvement in:
– 28-day mortality
– discharge alive at 28 days
– progression to invasive mechanical ventilation or deathhttps://t.co/mEtYq2qwkL pic.twitter.com/B0MNJWDi6e— Martin Landray (@MartinLandray) May 18, 2021
SARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment.
19 May, 2021 | 08:49h | UTCSARS-CoV-2 infects human pancreatic β-cells and elicits β-cell impairment – Cell Metabolism
Commentary on Twitter
A new report reinforces the capability for #SARSCoV2 to infect and kill pancreatic β-islet cells, affect insulin secretion https://t.co/4tpIVNpjTf @Cell_Metabolism #diabetes @StanfordMed @stanfordimmuno @UCSF and collaborators pic.twitter.com/dG027CXS5e
— Eric Topol (@EricTopol) May 18, 2021
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
19 May, 2021 | 08:40h | UTCScreening for Colorectal Cancer: US Preventive Services Task Force Recommendation Statement
Evidence Report: Screening for Colorectal Cancer: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force – JAMA
Editorials: US Preventive Services Task Force Recommendations for Colorectal Cancer Screening: Forty-Five Is the New Fifty – JAMA AND Updated USPSTF Guidelines for Colorectal Cancer Screening: The Earlier the Better – JAMA Surgery AND Colorectal Cancer Screening Starting at Age 45 Years—Ensuring Benefits Are Realized by All – JAMA Network Open AND
Modeling study: Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force – JAMA
Author interview: USPSTF Recommendation: Screening for Colorectal Cancer
JAMA Patient Page: Screening for Colorectal Cancer
M-A: Encephalitis as Neurological Complication of COVID‐19.
19 May, 2021 | 08:41h | UTC
ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections.
19 May, 2021 | 08:37h | UTC
Commentary on Twitter
📢New ACG Clinical Guideline on Prevention, Diagnosis & Treatment of C. difficile Infections
Focus on clinical challenges – diagnostic issues in diarrhea, distinguishing C. diff colonization from active infection + eval/mgmt of CDI in IBD
Full guideline: https://t.co/QTCzeLB9Ri pic.twitter.com/mqZUN4r4jA
— AJG – The American Journal of Gastroenterology (@AmJGastro) May 18, 2021
Fluid-induced harm in the hospital: look beyond volume and start considering sodium. From physiology towards recommendations for daily practice in hospitalized adults.
19 May, 2021 | 08:32h | UTC
The catastrophization effects of an MRI report on the patient and surgeon and the benefits of ‘clinical reporting’: results from an RCT and blinded trials.
19 May, 2021 | 08:25h | UTCRelated: You cannot unsee your MRI report AND Direct communication between radiologists and patients improves the quality of imaging reports – European Radiology
Commentary on Twitter
https://twitter.com/hjluks/status/1392151713700794374
Large cohort study confirms the renal toxicities of anti-inflammatories, suggesting Ibuprofen may be the safest option among them.
19 May, 2021 | 08:28h | UTCComparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD – Clinical Journal of the American Society of Nephrology (link to abstract – $ for full-text)
Commentary: Study: Ibuprofen Found Safest NSAID for the Kidney – MPR
Commentary on Twitter
Comparative Risks of Nonsteroidal Anti-Inflammatory Drugs on CKD
Read this new @CJASN study and listen to the accompanying podcast:https://t.co/GL1ITzh4O4 pic.twitter.com/lZGeFqfrDZ
— American Society of Nephrology (@ASNKidney) April 29, 2021
[Preprint] Practice Changing RCT: Therapeutic-dose anticoagulation with heparin (LMWH or unfractionated heparin) improves outcomes in non-critically ill patients with Covid-19 – the superiority of therapeutic-dose anticoagulation was seen in both high and low D-dimer groups.
18 May, 2021 | 08:04h | UTCTherapeutic Anticoagulation in Non-Critically Ill Patients with Covid-19 – medRxiv
Commentary on Twitter
Final results of the mpRCT now on preprint server. In non-critically ill patients with COVID-19 (n=2219), therapeutic-dose anticoagulation with heparins increases survival to hospital discharge with reduced use of organ support. https://t.co/TkhGs5qow5
— Ryan Zarychanski (@RZarychanski) May 17, 2021
#ACC21 – [Not published yet] RCT: Among hospitalized patients with Covid-19 and elevated D-Dimer, therapeutic anticoagulation with Rivaroxaban 20 mg was not associated with improved outcomes and resulted in increased major bleeding.
18 May, 2021 | 08:01h | UTCAntiCoagulaTIon cOroNavirus – ACTION – American College of Cardiology
Commentary: ACTION: Full-Dose Rivaroxaban Doesn’t Help in Hospitalized COVID-19 – TCTMD
COVID vaccines can block variant hitting Asia, lab study finds – “Assays using live SARS-CoV-2 offer hope that the vaccines made by Pfizer and Moderna will protect against a viral strain first seen in India”.
18 May, 2021 | 07:56h | UTCCOVID vaccines can block variant hitting Asia, lab study finds – Nature
See also: Pfizer, Moderna vaccines effective against Indian variants: study – MedicalXpress
Commentary on Twitter
Pfizer & Moderna mRNA vaccines are effective against multiple SARSCoV2 variants, including the B.1.617 & B.1.618, 2 variants underlying the surge in India. The research, while not yet peer-reviewed, was conducted at NYU School of Medicine in New York City https://t.co/3ziRhk8f4t pic.twitter.com/VzYQKWqyQF
— delthia ricks 🔬 (@DelthiaRicks) May 17, 2021
SARS-CoV-2 antibody-positivity protects against reinfection for at least seven months with 95% efficacy.
18 May, 2021 | 07:52h | UTC